Maxcyte, Inc. (MXCT) fundamentals score
Maxcyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development.
Services-Commercial Physical & Biological Research · Industrials · Listed on NASDAQ
Overall: 4.6 out of 10, Weak long-term fundamentals
- Growth: 3.1/10
- Profitability: 3.2/10
- Financial health: 5.7/10
- Earnings quality: 8.5/10
- Valuation: 4.1/10
Scores are calculated from Maxcyte, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Industrials stocks
- Sezzle Inc. (SEZL): 9.1/10
- Paymentus Holdings, Inc. (PAY): 8.7/10
- Argan Inc. (AGX): 8.6/10
- Ferguson Enterprises Inc. (FERG): 8.6/10
- International Seaways, Inc. (INSW): 8.6/10
- Dorian Lpg Ltd. (LPG): 8.6/10
- Quinstreet, Inc. (QNST): 8.6/10
- Remitly Global, Inc. (RELY): 8.6/10